Trinity Biotech: Down as co's unit receives FDA warning for Hemoglobin product

Trinity Biotech

17/08/2020 14:47

** U.S.-listed shares of diagnostic products maker  TRIB.O 
down 5.3% to $2.2
    ** Co says its subsidiary Primus Corp receives a warning
letter from U.S. FDA following an inspection of its Kansas City
manufacturing facility  urn:newsml:reuters.com:*:nGNX7WC2Y3
    ** Warning letter primarily relate to co's Hemoglobin
product, Ultra2 
    ** Co says it will provide response outlining actions it
will take within 15 business days from receipt of letter
    ** FDA conducted an inspection in January
    ** Up to Friday's close, stock had more than doubled YTD

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3463;))